来源：金融界 最新一期业绩显示，2025年一季报，公司实现营业收入1.24亿元，同比-26.92%；净利润-28791459.68 元，同比-1143.36%，销售毛利率66.36%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2澳华内镜-589.71295.774.7262.15亿行业平均 49.8447.964.65106.43亿行业中值36.6538.442.4547.58亿1天益医疗-1720.32-2946.711.8421.92亿3诺唯 赞-415.01-490.852.2888.81亿4爱朋医疗-368.22279.744.4430.21亿5博晖创新-326.27517.743.4847.87亿6硕 世生物-135.93-1986.301.2239.76亿7奥精医疗-120.78-177.021.5922.41亿8睿昂基因-97.79-80.291.3912.66亿 9康泰医学-85.34-72.113.0556.17亿10中红医疗-69.65-55.550.8848.40亿11华大智造-64.27-57.034.43342.67 亿 5月14日，澳华内镜今日收盘46.15元，下跌2 ...

Company Overview - Aohua Endoscopy's closing price on May 8 was 47.23 yuan, down 5.50%, with a latest price-to-book ratio of 4.83 and a total market capitalization of 6.36 billion yuan [1] - As of March 31, 2025, Aohua Endoscopy had 4,022 shareholders, a decrease of 469 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's main business includes the research, production, and sales of electronic endoscopy equipment and endoscopic surgical consumables [1] Financial Performance - In the latest quarterly report for Q1 2025, Aohua Endoscopy reported revenue of 124 million yuan, a year-on-year decrease of 26.92% [1] - The net profit for the same period was -28,791,459.68 yuan, representing a year-on-year decline of 1,143.36% [1] - The sales gross margin stood at 66.36% [1] Industry Comparison - Aohua Endoscopy's PE (TTM) is -603.51, while the industry average is 49.20, indicating a significant underperformance compared to peers [2] - The company's market capitalization of 6.36 billion yuan is lower than the industry median of 4.73 billion yuan [2] - Other companies in the industry show varying PE ratios, with some like Tianyi Medical at -1,748.07 and Nuo Wei Zhan at -418.55, indicating a challenging environment for medical device companies [2]

5月6日，澳华内镜今日收盘48.01元，上涨7.98%，最新市净率4.91，创100天以来新低，总市值64.65亿 元。 截至2025年一季报，共有30家机构持仓澳华内镜，其中基金27家、其他3家，合计持股数2493.70万股， 持股市值10.64亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)2澳华内镜-613.48307.694.9164.65亿行业平均 48.9047.004.53103.78亿行业中值36.4137.242.4046.92亿1天益医疗-1685.63-2887.291.8021.48亿3诺唯 赞-417.99-494.372.2989.45亿4博晖创新-329.61523.043.5248.36亿5爱朋医疗-325.82247.533.9226.73亿6硕 世生物-125.93-1840.221.1336.84亿7奥精医疗-117.01-171.501.5421.72亿8睿昂基因-98.61-80.961.4012.76亿 9康泰医学-84.98-71.803.0355.93亿10中红医疗-67.51-53.850.8546.92亿11华大智造-63.30-56.174. ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [8] Core Views - The company's 2024 performance met expectations, with total revenue of 750 million yuan, representing a year-on-year growth of 10.54%. Domestic market revenue was 586 million yuan, growing by 3.93%, while overseas revenue reached 161 million yuan, increasing by 42.70% [2][6][11] - The decline in domestic revenue growth is attributed to reduced procurement activities in the domestic terminal market, influenced by a decrease in the total amount of bidding [11] - The company is expanding its overseas marketing network, which is expected to sustain high growth rates in the future [11] - The company continues to focus on research and development, launching several new products in 2024, enhancing its competitive edge [11] Summary by Sections Financial Performance - In 2024, the company reported a net profit attributable to shareholders of 21.01 million yuan, a decrease of 63.68% year-on-year. The net profit after deducting non-recurring gains and losses was -6.29 million yuan, down 114.13% [6][11] - For Q1 2025, the company recorded a revenue of 124 million yuan, a decline of 26.92% year-on-year, with a net profit of -28.79 million yuan [6][11] Market Dynamics - The company is seeing a continuous increase in market share for its mid-to-high-end products, particularly the AQ-300 model in tertiary hospitals [11] - The company is actively promoting its products in county-level hospitals, enhancing diagnostic techniques and upgrading treatment models [11] Overseas Expansion - The overseas revenue growth of 42.70% in 2024 is attributed to successful product approvals and marketing efforts in multiple countries, which have significantly boosted brand influence [11] Research and Development - The company has established a robust R&D system with multiple locations, focusing on innovation in optical imaging, image processing, and key components for electronic endoscopes [11] - New product launches in 2024 include advanced endoscope systems, which are expected to strengthen the company's market position [11] Future Outlook - The company is projected to achieve net profits of 70 million, 100 million, and 139 million yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings ratios of 77, 54, and 39 times [11]

最新一期业绩显示，2024年年报，公司实现营业收入7.50亿元，同比10.54%；净利润2101.22万元，同 比-63.68%，销售毛利率68.12%。 股东方面，截至2025年3月31日，澳华内镜股东户数4022户，较上次减少469户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)117澳华内镜253.15253.153.8953.19亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.2411.51亿9热景生物-60.65-60.653.3310 ...